JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M611183200 on February 14, 2007

J. Biol. Chem., Vol. 282, Issue 14, 10203-10209, April 6, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/14/10203    most recent
M611183200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adlerz, L.
Right arrow Articles by Iverfeldt, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adlerz, L.
Right arrow Articles by Iverfeldt, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

IGF-1-induced Processing of the Amyloid Precursor Protein Family Is Mediated by Different Signaling Pathways*

Linda Adlerz{ddagger}, Sofia Holback{ddagger}, Gerd Multhaup§, and Kerstin Iverfeldt{ddagger}1

From the {ddagger}Department of Neurochemistry, Stockholm University, SE-10691 Stockholm, Sweden and the §Institute for Chemistry and Biochemistry, Free University of Berlin, D-14195 Berlin, Germany

Received for publication, December 6, 2006 , and in revised form, February 2, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The mammalian amyloid precursor protein (APP) protein family consists of the APP and the amyloid precursor-like proteins 1 and 2 (APLP1 and APLP2). The neurotoxic amyloid beta-peptide (Abeta) originates from APP, which is the only member of this protein family implicated in Alzheimer disease. However, the three homologous proteins have been proposed to be processed in similar ways and to have essential and overlapping functions. Therefore, it is also important to take into account the effects on the processing and function of the APP-like proteins in the development of therapeutic drugs aimed at decreasing the production of Abeta. Insulin and insulin-like growth factor-1 (IGF-1) have been shown to regulate APP processing and the levels of Abeta in the brain. In the present study, we show that IGF-1 increases {alpha}-secretase processing of endogenous APP and also increases ectodomain shedding of APLP1 and APLP2 in human SH-SY5Y neuroblastoma cells. We also investigated the role of different IGF-1-induced signaling pathways, using specific inhibitors for phosphatidylinositol 3-kinase and mitogen-activated protein kinase (MAPK). Our results indicate that phosphatidylinositol 3-kinase is involved in ectodomain shedding of APP and APLP1, but not APLP2, and that MAPK is involved only in the ectodomain shedding of APLP1.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The amyloid beta-peptide (Abeta)2 is the major constituent of senile plaques found in brains of patients suffering from Alzheimer disease (AD) (1, 2). This neurotoxic peptide originates from the amyloid precursor protein (APP) (3). APP together with its paralogues, the amyloid precursor-like proteins 1 and 2 (APLP1 and APLP2), comprise the mammalian APP protein family. Although APP has been thoroughly studied, its physiological function has not yet been established, and even less is known about the two homologous proteins. Double knock-out studies in mice have indicated that APP family proteins are essential for survival and that they possess partially redundant functions (4). APLP2 was suggested to play a more important role since APLP1–/–/APP–/– mice are viable and apparently normal, whereas APLP2–/–/APP–/– or APLP2–/–/APLP1–/– mice are perinatally lethal. However, gene silencing analysis in an in vitro study suggested that APLP1 rather than APLP2 may be more important for survival and differentiation (5). Earlier studies showed that the human APP gene could rescue the Drosophila homologue APPL deletion mutants, again indicating functional redundancy between the proteins in this family (6). In addition, deficiency in neuronal repair mechanisms after brain injury was observed in Drosophila after deletion of the gene coding for APPL, and both human APP and APPL could induce axonal aborization (7). Previously, we have shown that all members of the APP protein family are up-regulated in parallel with neurite outgrowth in human neuroblastoma SH-SY5Y cells subjected to retinoic acid (RA) (8). Functions during neurogenesis are also supported by in vivo studies in mice showing increased expression of the APP protein family during embryogenesis (9).

All APP family members are type 1 membrane proteins with a single membrane-spanning domain, a large exoplasmic N-terminal domain and a short cytoplasmic C-terminal domain (3, 10–13). In fact, the APP protein family is believed to function as cell surface receptors that signal through proteolytic processing followed by nuclear translocation of the cytoplasmic domain (APP intracellular domain or APP-like intracellular domain 1 or 2) (14–16). The processing of APP has been shown to be complex and to involve several different cleavage sites and proteolytic enzymes (reviewed in Refs. 17 and 18). Cleavage of APP at the beta-secretase site leads to secretion of the large N-terminal domain (sAPPbeta) and formation of a 99-amino-acid-long C-terminal membrane-bound fragment (C99). Subsequent cleavage by {gamma}-secretase results in the parallel formation of Abeta and APP intracellular domain. However, when APP is proteolytically processed at the {alpha}-secretase site, Abeta formation is precluded. Instead, sAPP{alpha} together with an 83-amino-acid-long C-terminal membrane-bound fragment (C83) are produced. Further cleavage of C83 by {gamma}-secretase leads to the production of APP intracellular domain and a smaller secreted peptide (p3). APLP1 and APLP2 have been shown to be proteolytically processed in similar ways (19–22) and to secrete their ectodomains (sAPLP1 and sAPLP2, respectively) into the surrounding environment (11, 23).

In addition to the receptor function attributed to the full-length proteins, the secreted fragments of the APP family proteins have been proposed to play physiological roles. sAPP has been suggested to be involved in cell survival and neurite outgrowth as well as to modulate neuronal excitability, synaptic plasticity, and synaptogenesis (reviewed in Ref. 24). sAPLP2 has also been shown to promote neurite outgrowth (25). Previously, we showed that the processing of APP, APLP1, and APLP2 increased in response to RA and brain-derived neurotrophic factor (26). In addition, our results suggested that RA and brain-derived neurotrophic factor shifted APP processing toward the {alpha}-secretase pathway since secretion of sAPP{alpha} increased, whereas the levels of the membrane-bound C-terminal fragment C99 decreased. Under these conditions, no secretion of sAPLP1 could be detected. Growth hormones such as nerve and epidermal growth factors have also been shown to lead to secretion of sAPP{alpha} (27) and sAPLP2 (23, 28). Furthermore, it was demonstrated that insulin increased extracellular levels of Abeta and sAPP{alpha} and at the same time decreased intracellular levels of Abeta (29). Interestingly, it has become evident in recent years that insulin and insulin-like growth factor-1 (IGF-1) signaling, besides regulating the energy balance of the brain, also modulates cognitive processes such as learning and memory as well as neuroprotection (reviewed in Ref. 30). In an AD transgenic mice model, IGF-1 was demonstrated to induce Abeta clearance from the brain by up-regulating levels of transport proteins such as albumin and transthyretin (31). IGF-1 treatment also resulted in enhanced cognitive performance, increased levels of synaptic proteins, and reduced astrogliosis associated with plaques (32). In addition, a positive correlation between Mini-Mental State Examination scores and serum IGF-1 concentrations in AD has been reported, and it was suggested that lower levels of IGF-1 might lead to cognitive impairment (33). These findings suggest components of the insulin/IGF-1 signaling pathways as potential therapeutic targets in AD.

Many studies on AD are focused on finding means to inhibit the production and accumulation of Abeta. However, based on the proposed essential functions of the APP family, it is of importance to further elucidate how the processing of APP and the other members of the APP protein family is regulated. In this study, we show that exposure of human neuroblastoma cells to IGF-1 results in increased secretion of sAPP{alpha}, sAPLP1, and sAPLP2 as well as decreased production of Abeta. In addition, using specific inhibitors for signaling pathways activated by IGF-1, we found that phosphatidylinositol 3-kinase (PI3-K), cyclin-dependent kinase 5 (cdk5), and mitogen-activated protein kinase (MAPK) have different impact on ectodomain shedding of the three homologous proteins.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture and Treatment—SH-SY5Y human neuroblastoma cells (American Type Culture Collection) were routinely maintained in minimum essential medium with Earl's salts, 10% fetal bovine serum, 100 units of/ml penicillin, 100 µg/ml streptomycin, 1% L-glutamine, and 1% non-essential amino acids as described previously (34). Cells were seeded at a density of 25,000 cells/cm2 in Nunc 60-mm dishes. At 24 h as well as 4 days after seeding, the medium was changed to serum-free culture medium (Dulbecco's modified Eagle's medium:F12 with the addition of N2 supplements, 100 units of/ml penicillin, 100 µg/ml streptomycin, and 1% L-glutamine). Cells were grown in 4 ml of serum-free culture medium for 6 days and then incubated for 45 min with 5 ml of serum-free culture medium devoid of insulin before treatment. Subsequently, cells were treated with 1 nM, 10 nM, or 1 µM insulin (Sigma-Aldrich) or 1, 5 or 10 nM IGF-1 (Sigma-Aldrich) for 18 h in 2 ml of serum- and insulin-free culture medium. For inhibition studies, 1 or 10 µM LY 294002 (Merck Biosciences), a specific PI3-K inhibitor, 5 or 20 µM PD 98059 (Merck Biosciences), a specific MAPK kinase (MEK) inhibitor, or 5 µM roscovitine (Sigma-Aldrich), a specific cdk5 inhibitor, was added to the cells during the washing step. The medium was then changed to serum- and insulin-free culture medium with 10 nM IGF-1 in the presence or absence of inhibitors. All cell culture reagents were purchased from Invitrogen unless otherwise indicated.

Western Blot Assay—Conditioned medium (2 ml) was collected and supplemented with Complete protease inhibitor mixture (Roche Applied Science) and concentrated as described previously (26). Cells were harvested and analyzed by Western blot assay as described previously (26). Concentrated culture medium from an equal number of cells (as determined by protein content in the cell lysate and corresponding to ~200 µl of conditioned medium) from each culture was loaded on a 7.5% Tris-glycine polyacrylamide gel. The concentrations of antibodies used were chosen to ensure relative quantitative measurements. Primary antibody concentrations were as follows: 1:4000 for 6E10 (directed against Abeta1–17) and CT11 (directed against the C-terminal 11 amino acids of APLP1), 1:3000 for 42464 (directed against amino acids 499–557 of APLP1, cf. 11), and 1:7500 for DTII (directed against full-length APLP2), and subsequently, 1:5000 for horseradish peroxidase-coupled anti-mouse IgG, anti-rabbit IgG, and protein A. Only bands that could not be observed in the absence of primary antibodies were quantified. All Western blotting reagents were from GE Healthcare or Bio-Rad Laboratories except CT11 and DTII, which were from Calbiochem, 6E10, which was from Signet Laboratories, and protein A, which was from Sigma-Aldrich.

ELISA—Conditioned medium and cell lysate were analyzed for Abeta40 in a high sensitivity sandwich ELISA according to the manufacturer (The Genetics Company Inc.). The Abeta concentration was normalized to the amount of cells in each culture (as determined by protein content in the cell lysate).

Statistical Analysis—Statistical analysis was performed using analysis of variance followed by Tukey-Kramer multiple comparison test. Data are presented as mean ± S.E. unless otherwise stated.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Increased Ectodomain Shedding of APP and APLP1 in Response to IGF-1—Human neuroblastoma SH-SY5Y cells were cultured for 18 h in the absence or presence of different concentrations of insulin. Conditioned media from the cultures were analyzed by Western blot using antibodies 6E10 (directed against Abeta1–17) and 42464 (directed against amino acids 499–557 of APLP1). The results showed that treatment with 1 µM insulin led to a significantly increased secretion of both sAPP{alpha} and sAPLP1 (Fig. 1A). Since insulin at this high concentration can activate both insulin and IGF-1 receptors, the effect of different concentrations of IGF-1 on the secretion of sAPP{alpha} and sAPLP1 was also investigated. IGF-1 treatment led to an ~10-fold increase in the release of sAPP{alpha} as well as sAPLP1 as compared with non-treated control cells (Fig. 1B). In contrast to the effects of insulin, significant effects were observed at low concentrations of IGF-1 (≥1 nM). IGF-1 treatment for 18 h did not affect the steady-state levels of the corresponding membrane-bound full-length proteins as shown by Western blot analysis of the cell lysate using antibody 6E10 and CT11 (directed against the C-terminal 11 amino acids of APLP1) (Fig. 1, C and D, and Table 1).


View this table:
[in this window]
[in a new window]

  		TABLE 1
Steady-state levels of full-length proteins

Levels of full-length proteins in cell lysate were determined using Western blot analysis with antibody CT11, 6E10, and DTII against APLP1, APP, and APLP2, respectively. Data represent mean ± S.D. from eight cultures derived from 3–4 independent experiments, and expressed as percentage of IGF-1 treated cells. All p values were considered not significant.

 


Figure 1
View larger version (70K):
[in this window]
[in a new window]

  		FIGURE 1.
Secretion of sAPP{alpha} and sAPLP1 increases in response to high concentrations of insulin and low concentrations of IGF-1. A and B, relative abundance of sAPP{alpha} (open bars) and sAPLP1 (closed bars) in culture medium from SH-SY5Y cells treated with insulin (A) and IGF-1 (B) for 18 h as indicated. Data represent mean ± S.E. from 9–10 cultures derived from 4 independent experiments. *, p < 0.05, **, p < 0.01, ***, p < 0.001, significantly different from non-treated control. Representative Western blot analyses, using antibody 42464 and 6E10 for sAPLP1 and sAPP{alpha}, respectively, are shown below each graph. The levels of the corresponding full-length proteins APLP1 and APP are not affected by either insulin (C) or IGF-1 (D) as shown by Western blot using antibody CT11 and 6E10 for APLP1 and APP, respectively.

 
PI3-K, MAPK, and cdk5 Are Involved in IGF-1-induced Secretion of sAPLP1—To investigate the mechanisms that may be involved in the effects of IGF-1 on APLP1 ectodomain shedding, inhibitors for different signaling pathways were used. 10 µM specific PI3-K inhibitor LY 294002 blocked the IGF-1-induced sAPLP1 secretion by ~90% (Fig. 2A). Furthermore, 20 µM specific MEK inhibitor PD 98059, and 5 µM specific cdk5 inhibitor roscovitine reduced the IGF-1-induced secretion of sAPLP1 by ~60 and 40%, respectively (Figs. 2A and 3). Treatment for 18 h with either of the inhibitors did not affect steady-state levels of the membrane-bound APLP1 (Fig. 2, lower panel, and Table 1).


Figure 2
View larger version (40K):
[in this window]
[in a new window]

  		FIGURE 2.
IGF-1-induced secretion of sAPP{alpha} and sAPLP1 is blocked by the PI3-K-specific inhibitor LY 294002, whereas the MEK-specific inhibitor PD 98059 selectively blocks secretion of sAPLP1. A and B, relative abundance of sAPLP1 (A) and sAPP{alpha} (B) in culture medium from SH-SY5Y cells treated with 10 nM IGF-1 in the presence or absence of 1 and 10 µM LY 294002 (LY1 and LY10, respectively) or 5 and 20 µM PD 98059 (PD5 and PD20, respectively) for 18 h as indicated. The expression levels of APLP1 and APP (A and B, lower panels, respectively) are not affected. Data represent mean ± S.E. from 9–24 cultures derived from 4–7 independent experiments. ***, p < 0.001, significantly different from cells treated with IGF-1. Note: Control (C) versus LY10 is not significantly different, whereas control versus 20 µM PD 98059 is significantly different (p < 0.01) for both sAPLP1 and sAPP{alpha}. Representative Western blot analyses using antibody 42464 for sAPLP1, CT11 for APLP1, and 6E10 for sAPP{alpha} and APP are shown below each graph.

 
PI3-K and cdk5, but Not MAPK, Are Involved in IGF-1-induced Secretion of sAPP{alpha}—The levels of sAPP{alpha} in conditioned media from cells treated with IGF-1 in the presence or absence of LY 294002, PD 98059, or roscovitine were also analyzed. In cells treated with IGF-1 in the presence of 10 µM LY 294002 or 5 µM roscovitine, secretion of sAPP{alpha} was reduced by ~80% (Figs. 2B and 3). On the contrary, 20 µM specific MEK inhibitor had no effect on the IGF-1-induced secretion of sAPP{alpha} (Fig. 2B). Treatment for 18 h with inhibitors had no effect on the steady-state levels of the membrane-bound APP (Fig. 2, lower panel, and Table 1).

Increased Ectodomain Shedding of APLP2 in Response to IGF-1 Does Not Involve PI3-K or MAPK—The effect of IGF-1 on the third member of the mammalian APP protein family was also investigated. Western blot analysis using antibodies DTII (directed against full-length APLP2) showed that IGF-1 significantly increased the secretion of sAPLP2 and CS GAG sAPLP2 (i.e. chondroitin sulfate glycosaminoglycan-modified sAPLP2) (Fig. 4). The increase of sAPLP2 secretion in response to 10 nM IGF-1 was not as dramatic as for APP and APLP1, ~3-fold as compared with ~10-fold (cf. Figs. 1 and 2). Furthermore, neither the PI3-K inhibitor nor the MEK inhibitor affected the IGF-1-induced secretion of sAPLP2 (Fig. 4). As a control, the polyvinylidene difluoride membranes were reprobed with antibody 6E10 (recognizing sAPP{alpha}) to show that in the same samples, a clear effect of the PI3-K inhibitor on the levels of sAPP{alpha} in the conditioned media could be observed (Fig. 4, B and C, upper panels).

Decreased Production of Abeta40 in Response to IGF-1—To further investigate the mechanisms behind IGF-1-induced processing of APP, conditioned medium and cell lysate were analyzed for Abeta40 by a high sensitive sandwich ELISA (Table 2). After treatment with IGF-1, the levels of both intra- and extracellular Abeta40 were decreased by ~30%. Effects of inhibitors for different signaling pathways were also analyzed, showing that in the presence of 10 µM LY 294002, the IGF-1-induced decrease in Abeta40 levels was reversed. However, as for the IGF-1-induced effects on sAPP{alpha}, 20 µM specific MEK inhibitor had no effect.


View this table:
[in this window]
[in a new window]

  		TABLE 2
Production of Abeta40 is reduced by IGF-1 treatment

Levels of Abeta40 were determined using a sandwich-ELISA. Data represent mean ± S.D. from 12–17 cultures derived from 3–8 independent experiments. *, p < 0.05, **, p < 0.01, significantly different from cells treated with IGF-1. Intracellular levels of Abeta40 after treatments with the inhibitors PD 98059 and roscovitine were not determined (ND).

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Previous studies have shown that processing of APP and secretion of sAPP increase in response to insulin (35). In the concentration range used (10 nM–1 µM), insulin can activate both the insulin and the IGF-1 receptor. The affinity of insulin and IGF-1 to their receptors lies within the range of 0.1–10 nM, whereas 100–500-fold higher concentrations are required for cross-activation of the receptors (reviewed in Ref. 36). The human neuroblastoma SH-SY5Y cells, used in the present study, have previously been shown to express functional insulin and IGF-1 receptors (37, 38). Our results suggest that the increased levels of sAPP{alpha} and sAPLP1 in response to either IGF-1 or insulin were mediated by activation of IGF-1 receptors.


Figure 3
View larger version (57K):
[in this window]
[in a new window]

  		FIGURE 3.
IGF-1-induced secretion of sAPP{alpha} and sAPLP1 is inhibited by the cdk5-specific inhibitor roscovitine. Shown is the relative abundance of sAPP{alpha} (open bars) and sAPLP1 (closed bars) in culture medium from SH-SY5Y cells treated with 10 nM IGF-1 in the presence or absence of 5 µM roscovitine (RO5) for 18 h as indicated. Data represent mean ± S.E. from 9–11 cultures derived from 4 independent experiments. *, p < 0.05, ***, p < 0.001, significantly different from cells treated with IGF-1. Note: Control (C) versus 5 µM roscovitine for sAPLP1 is significantly different (p < 0.01), whereas control versus 5 µM roscovitine for sAPP{alpha} is not significantly different. Representative Western blot analyses, using antibody 6E10 and 42464 for sAPP{alpha} and sAPLP1, respectively, are shown below each graph.

 
Activation of insulin and IGF-1 receptors triggers two major signaling pathways, the PI3-K or MAPK cascades that ultimately lead to proliferation, differentiation, or survival (reviewed in Ref. 39). It has previously been shown that high concentrations of insulin regulate sAPP release via a PI3-K-dependent signaling pathway (35). We observed that a specific PI3-K inhibitor totally abolished the increase in sAPP{alpha} levels in response to IGF-1. In contrast, a specific MEK inhibitor did not significantly reduce the elevated levels of sAPP{alpha}, excluding the involvement of the MAPK signaling cascade. Previously, we have shown that RA increases the secretion of sAPP{alpha} concomitant with neurite outgrowth (8, 26). PI3-K signaling has been shown to be required for RA-induced differentiation of SH-SY5Y cells (40). It can be speculated that effects on sAPP{alpha} secretion and neurite outgrowth are mediated by the same signaling pathways. However, both PI3-K and MAPK were shown to be involved in IGF-1-induced neurite outgrowth in SH-SY5Y cells (38). In addition, it has also been shown that RA increases the expression of cdk5 and p35 as well as stimulates neurite outgrowth through the MAPK pathway in another human neuroblastoma cell line (41). Here we observed that a specific cdk5 inhibitor completely blocked the IGF-1-induced secretion of sAPP{alpha}, suggesting that cdk5 plays a central role in the IGF-1-induced processing of APP. Indeed, several other studies have indicated a connection between cdk5 and APP. On one hand, a novel neuroprotective function of sAPP in preventing tau hyperphosphorylation via suppression of overactivation of cdk5 has been suggested (42). On the other hand, cdk5 has been suggested to be involved in the regulation of APP processing. Activation of cdk5 by overexpression of p25 or p35 in SH-SY5Y cells led to phosphorylation of APP at Thr-668 (43). The same study also showed that activation of cdk5 in cells overexpressing APP with the Swedish mutation resulted in higher levels of secreted Abeta, sAPPbeta, and sAPP{alpha} without affecting the steady-state levels of APP. The same group also reported that inhibition of cdk5 by roscovitine led to increased hippocampal levels of Abeta in an AD mice model (44). Thus, the role of cdk5 in Abeta production and accumulation is not completely clear.

Enhanced production, aberrant catabolism, or abnormal transport of Abeta across the blood-brain barrier are processes that all could contribute to increased levels of Abeta inside the brain. Several enzymes have the capability to cleave Abeta, and neprilysin has been suggested to play the most important role (reviewed in Ref. 45). Another physiologically relevant Abeta-degrading enzyme is insulin-degrading enzyme (46). As substrates, insulin and Abeta will compete for insulin-degrading enzyme. It has been speculated that age-related reduction of IGF-1 signaling leads to decreased transport of Abeta over the blood-brain barrier. The resulting elevated levels of Abeta in the brain may in turn lead to antagonized insulin receptor binding (loss of insulin sensitivity). As a consequence, increased insulin levels may follow and interfere with Abeta degradation and further contribute to increased Abeta load in the brain (30). In our study, we showed that IGF-1 led to a reduction in intraas well as extracellular levels of Abeta40 and that the PI3-K inhibitor totally reversed these effects. On the other hand, PD 98059 had no effect on secreted Abeta40 levels, again indicating that MAPK is not involved in IGF-1-induced processing of APP. The levels of secreted Abeta42, considered to be the most toxic form, were close to, or below, the detection limit, and accurate measurements could not be obtained (data not shown). However, the effects on Abeta42 secretion in response to the various treatments were similar to the effects on Abeta40 and, likewise, the presence of the PI3-K inhibitor resulted in significantly increased levels of Abeta42 (p < 0.01, n = 6). Together, our results clearly indicate that IGF-1 treatment leads to a shift in APP processing toward the {alpha}-secretase pathway instead of the amyloidogenic pathway.

Previously, it has been proposed that the members of the APP family are processed in a similar way (19–22). In this study, a cell line with endogenous expression of all three proteins in the mammalian APP family was used. We observed that processing of APP and APLP1 and secretion of sAPP{alpha} and sAPLP1 were increased to the same extent in response to insulin or IGF-1. As for sAPP{alpha}, the IGF-1-induced increase in sAPLP1 returned to control levels after treatment with LY 294002 and was partly inhibited by roscovitine. Interestingly, and in contrast to sAPP{alpha}, PD 98059 inhibited the IGF-1-induced sAPLP1 release. APP and APLP2 are considered to be the most closely related members of the APP family. Contradictorily, we show that the PI3-K inhibitor that totally blocked the sAPP{alpha} secretion did not have any effect on the secretion of sAPLP2 or CS GAG sAPLP2. However, similar to sAPP{alpha}, and in contrast to sAPLP1, the MEK inhibitor did not affect the IGF-1-induced secretion of sAPLP2. A previous study from our group also indicated differences in the regulation of the processing of the APP protein family (8). These data suggested that a PKC inhibitor, curcumin, had no effect on APLP1, blocked APLP2, and partly blocked APP ectodomain shedding. The results from our two studies indicate that the regulation of APLP1 and APLP2 is more different from each other than from APP.


Figure 4
View larger version (53K):
[in this window]
[in a new window]

  		FIGURE 4.
Secretion of sAPLP2 increases in response to IGF-1 and is affected neither by the MEK-specific inhibitor PD 98059 nor by the PI3-K-specific inhibitor LY 294002. A, relative abundance of sAPLP2 in culture medium from SH-SY5Y cells treated with 10 nM IGF-1 in the absence or presence of 20 µM PD 98059 (PD20) or 10 µM LY 294002 (LY10) for 18 h as indicated. Data represent mean ± S.E. from nine cultures derived from 3 independent experiments. *, p < 0.05, significantly different from cells treated with IGF-1. B, representative Western blot analyses using antibody DTII for sAPLP2, CS GAG sAPLP2 (i.e. chondroitin sulfate glycosaminoglycan-modified sAPLP2), and APLP2 and CS GAG APLP2. C, the same polyvinylidene difluoride membranes as in B reprobed with antibody 6E10 for sAPP{alpha} to emphasize the differential effect of the PI3-K inhibitor on sAPLP2 and sAPP.

 
In conclusion, in the present study, we show that ectodomain shedding of the APP family is induced by IGF-1. However, the effect of inhibitors specific for different signaling pathways indicates that the mechanisms behind the IGF-1-induced processing of the different APP family proteins are not identical. We propose that PI3-K is involved in ectodomain shedding of APP and APLP1, but not APLP2, and that MAPK is involved only in the ectodomain shedding of APLP1. In addition, cdk5 was shown to be involved in the processing of both APP and APLP1. Proteolytic processing of APP and APLPs may be modulated by regulation of enzyme activity, by specific post-translational modifications of the substrate, or by altered subcellular localization of the substrate or the enzyme. More studies are needed to put together all the clues about the processing and the signaling pathways involved. This will lead to a more complete understanding of the physiological function of the APP protein family.


   FOOTNOTES
 
* This work was supported by the Magn. Bergvalls Stiftelse, Alzheimerfonden, Längmanska kulturfonden and Stiftelsen för Gamla Tjänarinnor. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed. Tel.: 46-8-164268; Fax: 46-8-161371; E-mail: kerstin{at}neurochem.su.se.

2 The abbreviations used are: Abeta, amyloid beta-peptide; APP, amyloid precursor protein; sAPP, secreted APP; AD, Alzheimer disease; APLP, APP-like protein; sAPLP, secreted APLP; RA, retinoic acid; CS GAG, chondroitin sulphate glycosaminoglycan; PI3-K, phosphatidylinositol 3-kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK kinase; IGF-1, insulin-like growth factor-1; cdk5, cyclin-dependent kinase 5; ELISA, enzyme-linked immunosorbent assay. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Allsop, D., Landon, M., and Kidd, M. (1983) Brain Res. 259, 348–352[CrossRef][Medline] [Order article via Infotrieve]
  2. Glenner, G. G., and Wong, C. W. (1984) Biochem. Biophys. Res. Commun. 120, 885–890[CrossRef][Medline] [Order article via Infotrieve]
  3. Kang, J., Lemaire, H. G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K. H., Multhaup, G., Beyreuther, K., and Müller-Hill, B. (1987) Nature 325, 733–736[CrossRef][Medline] [Order article via Infotrieve]
  4. Heber, S., Herms, J., Gajic, V., Hainfellner, J., Aguzzi, A., Rülicke, T., von Kretzschmar, H., von Koch, C., Sisodia, S., Tremml, P., Lipp, H. P., Wolfer, D. P., and Müller, U. (2000) J. Neurosci. 20, 7951–7963[Abstract/Free Full Text]
  5. Sakai, T., and Hohjoh, H. (2006) Cell Biol. Int. 11, 952–956
  6. Luo, L., Tully, T., and White, K. (1992) Neuron 9, 595–605[CrossRef][Medline] [Order article via Infotrieve]
  7. Leyssen, M., Ayaz, D., Hebert, S. S., Reeve, S., De Strooper, B., and Hassan, B. A. (2005) EMBO J. 24, 2944–2955[CrossRef][Medline] [Order article via Infotrieve]
  8. Adlerz, L., Beckman, M., Holback, S., Tehranian, R., Cortes Toro, V., and Iverfeldt, K. (2003) Brain Res. Mol. Brain Res. 119, 62–72[Medline] [Order article via Infotrieve]
  9. Lorent, K., Overbergh, L., Moechars, D., De Strooper, B., Van Leuven, F., and Van den Berghe, H. (1995) Neuroscience 65, 1009–1025[CrossRef][Medline] [Order article via Infotrieve]
  10. Dyrks, T., Weidemann, A., Multhaup, G., Salbaum, J. M., Lemaire, H. G., Kang, J., Müller-Hill, B., Masters, C. L., and Beyreuther, K. (1988) EMBO J. 7, 949–957[Medline] [Order article via Infotrieve]
  11. Paliga, K., Peraus, G., Kreger, S., Dürrwang, U., Hesse, L., Multhaup, G., Masters, C. L., Beyreuther, K., and Weidemann, A. (1997) Eur. J. Biochem. 250, 354–363[Medline] [Order article via Infotrieve]
  12. Sprecher, C. A., Grant, F. J., Grimm, G., O'Hara, P. J., Norris, F., Norris, K., and Foster, D. C. (1993) Biochemistry 32, 4481–4486[CrossRef][Medline] [Order article via Infotrieve]
  13. Wasco, W., Gurubhagavatula, S., Paradis, M. D., Romano, D. M., Sisodia, S. S., Hyman, B. T., Neve, R. L., and Tanzi, R. E. (1993) Nat. Genet. 5, 95–100[CrossRef][Medline] [Order article via Infotrieve]
  14. Cao, X., and Südhof, T. C. (2001) Science 293, 115–120[Abstract/Free Full Text]
  15. Cupers, P., Orlans, I., Craessaerts, K., Annaert, W., and De Strooper, B. (2001) J. Neurochem. 78, 1168–1178[CrossRef][Medline] [Order article via Infotrieve]
  16. Kimberly, W. T., Zheng, J. B., Guenétte, S. Y., and Selkoe, D. J. (2001) J. Biol. Chem. 276, 40288–40292[Abstract/Free Full Text]
  17. Vardy, E. R., Catto, A. J., and Hooper, N. M. (2005) Trends Mol. Med. 11, 464–472[CrossRef][Medline] [Order article via Infotrieve]
  18. Esler, W. P., and Wolfe, M. S. (2001) Science 293, 1449–1454[Abstract/Free Full Text]
  19. Li, Q., and Südhof, T. C. (2004) J. Biol. Chem. 279, 10542–10550[Abstract/Free Full Text]
  20. Pastorino, L., Ikin, A. F., Lamprianou, S., Vacaresse, N., Revelli, J. P., Platt, K., Paganetti, P., Mathews, P. M., Harroch, S., and Buxbaum, J. D. (2004) Mol. Cell Neurosci. 25, 642–649[CrossRef][Medline] [Order article via Infotrieve]
  21. Endres, K., Postina, R., Schroeder, A., Mueller, U., and Fahrenholz, F. (2005) FEBS J. 272, 5808–5820[CrossRef][Medline] [Order article via Infotrieve]
  22. Eggert, S., Paliga, K., Soba, P., Evin, G., Masters, C. L., Weidemann, A., and Beyreuther, K. (2004) J. Biol. Chem. 279, 18146–18156[Abstract/Free Full Text]
  23. Webster, M. T., Groome, N., Francis, P. T., Pearce, B. R., Sherriff, F. E., Thinakaran, G., Felsenstein, K. M., Wasco, W., Tanzi, R. E., and Bowen, D. M. (1995) Biochem. J. 310, 95–99[Medline] [Order article via Infotrieve]
  24. Mattson, M. P. (1997) Physiol. Rev. 77, 1081–1132[Abstract/Free Full Text]
  25. Cappai, R., Mok, S. S., Galatis, D., Tucker, D. F., Henry, A., Beyreuther, K., Small, D. H., and Masters, C. L. (1999) FEBS Lett. 442, 95–98[CrossRef][Medline] [Order article via Infotrieve]
  26. Holback, S., Adlerz, L., and Iverfeldt, K. (2005) J. Neurochem. 95, 1059–1068[CrossRef][Medline] [Order article via Infotrieve]
  27. Refolo, L. M., Salton, S. R., Anderson, J. P., Mehta, P., and Robakis, N. K. (1989) Biochem. Biophys. Res. Commun. 164, 664–670[CrossRef][Medline] [Order article via Infotrieve]
  28. Xu, K. P., Zoukhri, D., Zieske, J. D., Dartt, D. A., Sergheraert, C., Loing, E., and Yu, F. S. (2001) Am. J. Physiol. 281, C603–C614
  29. Gasparini, L., Gouras, G. K., Wang, R., Gross, R. S., Beal, M. F., Greengard, P., and Xu, H. (2001) J. Neurosci. 21, 2561–2570[Abstract/Free Full Text]
  30. Carro, E., and Torres-Aleman, I. (2004) Eur. J. Pharmacol. 490, 127–133[CrossRef][Medline] [Order article via Infotrieve]
  31. Carro, E., Trejo, J. L., Gomez-Isla, T., LeRoith, D., and Torres-Aleman, I. (2002) Nat. Med. 8, 1390–1397[CrossRef][Medline] [Order article via Infotrieve]
  32. Carro, E., Trejo, J. L., Gerber, A., Loetscher, H., Torrado, J., Metzger, F., and Torres-Aleman, I. (2006) Neurobiol. Aging 27, 1250–1257[CrossRef][Medline] [Order article via Infotrieve]
  33. Watanabe, T., Miyazaki, A., Katagiri, T., Yamamoto, H., Idei, T., and Iguchi, T. (2005) J. Am. Geriatr. Soc. 53, 1748–1753[Medline] [Order article via Infotrieve]
  34. Beckman, M., and Iverfeldt, K. (1997) Neurosci. Lett. 221, 73–76[CrossRef][Medline] [Order article via Infotrieve]
  35. Solano, D. C., Sironi, M., Bonfini, C., Solerte, S. B., Govoni, S., and Racchi, M. (2000) FASEB J. 14, 1015–1022[Abstract/Free Full Text]
  36. Navarro, I., Leibush, B., Moon, T. W., Plisetskaya, E. M., Banos, N., Mendez, E., Planas, J. V., and Gutierrez, J. (1999) Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 122, 137–153[CrossRef][Medline] [Order article via Infotrieve]
  37. Mattsson, M. E., Hammerling, U., Mohall, E., Hall, K., and Pahlman, S. (1990) Growth Factors 2, 251–265[Medline] [Order article via Infotrieve]
  38. Kim, B., van Golen, C. M., and Feldman, E. L. (2004) Oncogene. 23, 130–141[CrossRef][Medline] [Order article via Infotrieve]
  39. Dupont, J., Dunn, S. E., Barrett, J. C., and LeRoith, D. (2003) Recent Prog. Horm. Res. 58, 325–342[Abstract/Free Full Text]
  40. Lopez-Carballo, G., Moreno, L., Masia, S., Perez, P., and Barettino, D. (2002) J. Biol. Chem. 277, 25297–25304[Abstract/Free Full Text]
  41. Lee, J. H., and Kim, K. T. (2004) J. Neurochem. 91, 634–647[CrossRef][Medline] [Order article via Infotrieve]
  42. Han, P., Dou, F., Li, F., Zhang, X., Zhang, Y. W., Zheng, H., Lipton, S. A., Xu, H., and Liao, F. F. (2005) J. Neurosci. 25, 11542–11552[Abstract/Free Full Text]
  43. Liu, F., Su, Y., Li, B., Zhou, Y., Ryder, J., Gonzalez-DeWhitt, P., May, P. C., and Ni, B. (2003) FEBS Lett. 547, 193–196[CrossRef][Medline] [Order article via Infotrieve]
  44. Ryder, J., Su, Y., Liu, F., Li, B., Zhou, Y., and Ni, B. (2003) Biochem. Biophys. Res. Commun. 312, 922–929[CrossRef][Medline] [Order article via Infotrieve]
  45. Wang, D. S., Dickson, D. W., and Malter, J. S. (2006) J. Biomed. Biotechnol. 2006, 58406[Medline] [Order article via Infotrieve]
  46. Kurochkin, I. V., and Goto, S. (1994) FEBS Lett. 345, 33–37[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/14/10203    most recent
M611183200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adlerz, L.
Right arrow Articles by Iverfeldt, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adlerz, L.
Right arrow Articles by Iverfeldt, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.